Enveric Biosciences (ENVB) Short Interest Ratio & Short Volume $1.17 -0.06 (-4.88%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$1.20 +0.03 (+2.14%) As of 04/17/2025 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Enveric Biosciences Short Interest DataEnveric Biosciences (ENVB) has a short interest of 179,500 shares, representing 7.74% of the float (the number of shares available for trading by the public). This marks a -25.55% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.1, indicating that it would take 0.1 days of the average trading volume of 729,667 shares to cover all short positions.Current Short Interest179,500 sharesPrevious Short Interest241,100 sharesChange Vs. Previous Month-25.55%Dollar Volume Sold Short$249,505.00Short Interest Ratio0.1 Days to CoverLast Record DateMarch 31, 2025Outstanding Shares678,000 sharesFloat Size2,320,000 sharesShort Percent of Float7.74%Today's Trading Volume37,993 sharesAverage Trading Volume729,667 sharesToday's Volume Vs. Average5% Short Selling Enveric Biosciences? Sign up to receive the latest short interest report for Enveric Biosciences and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartENVB Short Interest Over TimeENVB Days to Cover Over TimeENVB Percentage of Float Shorted Over Time Enveric Biosciences Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/31/2025179,500 shares $249,505.00 -25.6%7.7%0.1 $1.39 3/15/2025241,100 shares $417,103.00 -80.6%13.3%0.1 $1.73 2/28/20251,240,000 shares $3.47 million +351.4%77.5%0.5 $2.80 2/15/2025274,700 shares $439,520.00 +17.8%15.2%0.1 $1.60 1/31/2025233,200 shares $487,388.00 -42.8%16.9%1.5 $2.09 1/15/2025407,400 shares $145,441.80 +498.2%4.3%0.8 $0.36 12/31/202468,100 shares $24,407.04 -56.7%0.7%0.1 $0.36 12/15/2024157,200 shares $57,142.20 +36.1%1.7%0.3 $0.36 11/30/2024115,500 shares $38,115.00 -57.6%1.2%0.2 $0.33 11/15/2024272,200 shares $100,714.00 -17.6%3.0%0.5 $0.37 Get the Latest News and Ratings for ENVB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Enveric Biosciences and its competitors with MarketBeat's FREE daily newsletter. 10/31/2024330,200 shares $164,835.84 +70.9%4.1%0.7 $0.50 10/15/2024193,200 shares $81,723.60 -2.9%2.4%0.1 $0.42 9/30/2024199,000 shares $94,326.00 -2.8%2.3%0.2 $0.47 9/15/2024204,700 shares $102,554.70 -38.3%2.3%0.2 $0.50 8/31/2024332,000 shares $168,456.80 -29.2%3.8%0.3 $0.51 8/15/2024469,100 shares $226,575.30 -80.9%5.3%0.4 $0.48 7/31/20242,450,000 shares $1.15 million +1,760.3%31.2%1.7 $0.47 7/15/2024131,700 shares $71,381.40 -13.4%1.7%0.2 $0.54 6/30/2024152,100 shares $95,245.02 -43.4%2.0%0.3 $0.63 6/15/2024268,800 shares $198,912.00 -20.5%3.5%0.5 $0.74 5/31/2024338,100 shares $263,718.00 -50.2%4.5%0.2 $0.78 5/15/2024678,900 shares $534,973.20 +736.1%8.9%0.1 $0.79 4/30/202481,200 shares $76,328.00 -15.1%1.1%0 $0.94 4/15/202495,600 shares $88,095.40 -62.5%1.4%0 $0.92 3/31/2024254,900 shares $254,900.00 +69.5%4.2%0.1 $1.00 3/15/2024150,400 shares $162,432.00 +58.2%3.2%0 $1.08 2/29/202495,100 shares $137,895.00 +47.0%4.2%0 $1.45 2/15/202464,700 shares $54,283.30 +181.3%2.5%0.2 $0.84 1/31/202423,000 shares $16,932.60 -58.6%0.9%0.2 $0.74 1/15/202455,600 shares $71,168.00 +334.4%2.3%1.4 $1.28 12/31/202312,800 shares $16,640.00 +6.7%0.6%0.4 $1.30 12/15/202312,000 shares $16,080.00 +263.6%0.6%0.7 $1.34 11/30/20233,300 shares $4,884.00 -54.8%0.2%0.2 $1.48 11/15/20237,300 shares $10,402.50 -62.4%0.4%0.4 $1.43 10/31/202319,400 shares $33,368.00 -19.5%1.0%0.9 $1.72 10/15/202324,100 shares $50,851.00 +121.1%1.3%0.3 $2.11 9/30/202310,900 shares $25,942.00 -55.0%0.6%0.1 $2.38 9/15/202324,200 shares $55,176.00 -45.3%1.2%0.3 $2.28 8/31/202344,200 shares $95,472.00 -42.3%2.3%0.4 $2.16 8/15/202376,600 shares $182,308.00 +86.4%4.0%0.1 $2.38Something strange going on at Mar-a-Lago (Ad)A former government advisor says a $9 trillion AI breakthrough is nearing launch. It may become America’s biggest advantage in the race against China — and a handful of Musk-linked companies could benefit.Nvidia’s early days made millionaires. This AI play might too. 7/31/202341,100 shares $109,737.00 +95.7%2.2%0 $2.67 7/15/202321,000 shares $60,270.00 -43.1%1.1%0 $2.87 6/30/202336,900 shares $124,353.00 -65.6%2.0%0 $3.37 6/15/2023107,400 shares $414,564.00 -69.1%5.8%0 $3.86 5/31/2023347,300 shares $1.46 million +1,430.0%18.7%0.1 $4.19 5/15/202322,700 shares $34,050.00 -30.2%1.2%0 $1.50 4/30/202332,500 shares $59,520.50 +44.4%1.8%1 $1.83 4/15/202322,500 shares $34,200.00 +39.8%1.2%0.6 $1.52 3/31/202316,100 shares $26,793.62 +64.3%0.9%0.6 $1.66 3/15/20239,800 shares $16,954.00 +71.9%0.6%0.3 $1.73 2/28/20235,700 shares $11,913.00 -38.0%0.3%0.1 $2.09 2/15/20239,200 shares $24,932.00 -37.8%0.5%0.2 $2.71 1/31/202314,800 shares $42,476.00 -53.6%0.8%0.3 $2.87 1/15/202331,900 shares $90,277.00 -21.2%1.7%0.7 $2.83 12/30/202240,500 shares $84,240.00 -11.2%2.0%0.7 $2.08 12/15/202245,600 shares $97,584.00 +27.4%2.3%0.9 $2.14 11/30/202235,800 shares $102,746.00 -17.5%1.8%0.5 $2.87 11/15/202243,400 shares $147,560.00 -37.7%2.2%0.4 $3.40 10/31/202269,700 shares $237,677.00 +36.1%4.7%0.3 $3.41 10/15/202251,200 shares $175,104.00 +55.2%3.6%0.1 $3.42 9/30/202233,000 shares $139,260.00 -60.1%2.3%0.1 $4.22 9/15/202282,800 shares $477,756.00 +11.7%5.8%0.2 $5.77 8/31/202274,100 shares $413,478.00 -21.7%5.4%0.2 $5.58 8/15/202294,600 shares $624,360.00 -43.4%6.9%0.2 $6.60 7/31/2022167,000 shares $1.07 million +158.5%16.7%0.6 $6.40 7/15/202264,600 shares $25.71 million +36.6%7.5%0.8 $398.00 6/30/20222,360,000 shares $505,748.00 -23.9%N/A0.9 $0.21 6/15/20223,100,000 shares $651,000.00 -4.6%N/A1.6 $0.21 5/31/20223,250,000 shares $642,525.00 -2.1%N/A1.5 $0.20 5/15/20223,320,000 shares $664,000.00 -2.4%N/A1.1 $0.20 4/30/20223,400,000 shares $918,340.00 +165.6%N/A1 $0.27 4/15/20221,280,000 shares $384,384.00 -19.5%N/A0.4 $0.30 3/31/20221,590,000 shares $524,700.00 -17.6%N/A0.6 $0.33 3/15/20221,930,000 shares $536,540.00 +498.1%N/A0.8 $0.28 2/28/2022322,700 shares $88,581.15 -67.6%N/A0.1 $0.27 2/15/2022996,300 shares $313,834.50 +421.9%N/A0.8 $0.32 1/31/2022190,900 shares $121,469.67 -67.1%N/A0.3 $0.64 1/15/2022580,200 shares $434,453.76 +143.0%N/A0 $0.75 12/31/2021238,800 shares $222,084.00 -41.9%N/A0.3 $0.93 12/15/2021411,300 shares $435,978.00 -50.8%N/A0.3 $1.06 11/30/2021835,400 shares $1.09 million -45.0%4.0%0.4 $1.30 11/15/20211,520,000 shares $2.74 million -22.5%7.3%0.4 $1.80 10/29/20211,960,000 shares $3.45 million +16.0%13.8%0.5 $1.76 10/15/20211,690,000 shares $3.19 million +33.1%10.9%0.5 $1.89 9/30/20211,270,000 shares $2.63 million -44.5%8.2%0.4 $2.07 9/15/20212,290,000 shares $6.07 million +178.1%14.2%0.7 $2.65 8/31/2021823,600 shares $1.64 million -5.0%5.1%0.3 $1.99 8/13/2021866,800 shares $1.49 million -9.4%5.4%0.7 $1.72 7/30/2021956,800 shares $1.83 million +8.2%5.9%0.7 $1.91 7/15/2021884,400 shares $1.82 million +17.3%5.5%0.6 $2.06Something strange going on at Mar-a-Lago (Ad)A former government advisor says a $9 trillion AI breakthrough is nearing launch. It may become America’s biggest advantage in the race against China — and a handful of Musk-linked companies could benefit.Nvidia’s early days made millionaires. This AI play might too. 6/30/2021754,300 shares $1.80 million +37.8%4.7%0.5 $2.38 6/15/2021547,600 shares $1.21 million -48.3%3.4%0.3 $2.21 5/28/20211,060,000 shares $2.36 million +183.1%6.5%0.4 $2.23 5/14/2021374,400 shares $711,360.00 -30.3%2.3%0.1 $1.90 4/30/2021536,900 shares $1.33 million -41.1%3.4%0.1 $2.48 4/15/2021911,800 shares $2.28 million +17.5%5.7%0.1 $2.50 3/31/2021776,000 shares $2.30 million +34.6%5.6%0.1 $2.97 3/15/2021576,400 shares $2.13 million +233.8%4.1%0.1 $3.70 2/26/2021172,700 shares $628,628.00 -9.4%2.0%0.1 $3.64 2/12/2021190,700 shares $928,709.00 +110.0%2.2%0.1 $4.87 1/29/202190,800 shares $345,948.00 -42.4%10.0%0.1 $3.81 1/15/2021157,700 shares $657,609.00 No Change17.4%0.2 $4.17 ENVB Short Interest - Frequently Asked Questions What is Enveric Biosciences' current short interest? Short interest is the volume of Enveric Biosciences shares that have been sold short but have not yet been covered or closed out. As of March 31st, traders have sold 179,500 shares of ENVB short. 7.74% of Enveric Biosciences' shares are currently sold short. Learn More on Enveric Biosciences' current short interest. Which institutional investors are shorting Enveric Biosciences? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Enveric Biosciences: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Enveric Biosciences? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 7.74% of Enveric Biosciences' floating shares are currently sold short. Is Enveric Biosciences' short interest increasing or decreasing? Enveric Biosciences saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 179,500 shares, a decline of 25.5% from the previous total of 241,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Enveric Biosciences' float size? Enveric Biosciences currently has issued a total of 678,000 shares. Some of Enveric Biosciences' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Enveric Biosciences currently has a public float of 2,320,000 shares. How does Enveric Biosciences' short interest compare to its competitors? 7.74% of Enveric Biosciences' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Enveric Biosciences: Sonoma Pharmaceuticals, Inc. (3.94%), Lixte Biotechnology Holdings, Inc. (1.60%), SciSparc Ltd. (5.63%), IM Cannabis Corp. (0.39%), Virax Biolabs Group Limited (3.44%), Jaguar Health, Inc. (9.15%), Elevai Labs, Inc. (2.58%), Artelo Biosciences, Inc. (0.05%), Ensysce Biosciences, Inc. (2.62%), Synaptogenix, Inc. (0.88%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.93 billion), iShares 20+ Year Treasury Bond ETF ($9.31 billion), Strategy Incorporated ($8.42 billion), Charter Communications, Inc. ($4.52 billion), Apollo Global Management, Inc. ($4.26 billion), Super Micro Computer, Inc. ($3.98 billion), Capital One Financial Co. ($3.79 billion), TC Energy Co. ($3.43 billion), AppLovin Co. ($2.91 billion), and Schlumberger Limited ($2.89 billion). View all of the most shorted stocks. What does it mean to sell short Enveric Biosciences stock? Short selling ENVB is an investing strategy that aims to generate trading profit from Enveric Biosciences as its price is falling. ENVB shares are trading down $0.06 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Enveric Biosciences? A short squeeze for Enveric Biosciences occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ENVB, which in turn drives the price of the stock up even further. How often is Enveric Biosciences' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ENVB, twice per month. The most recent reporting period available is March, 31 2025. More Short Interest Resources from MarketBeat Related Companies Sonoma Pharmaceuticals Short Interest Lixte Biotechnology Short Interest SciSparc Short Interest IM Cannabis Short Interest Virax Biolabs Group Short Interest Jaguar Health Short Interest Elevai Labs Short Interest Artelo Biosciences Short Interest Ensysce Biosciences Short Interest Synaptogenix Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ENVB) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enveric Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enveric Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ENVB Stock Free ENVB Stock Alerts